Page last updated: 2024-12-07

alpha-fluoromethylhistidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

alpha-fluoromethylhistidine: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID188141
CHEMBL ID4117252
SCHEMBL ID60507
MeSH IDM0091260

Synonyms (16)

Synonym
alpha-fluoromethylhistidine
73804-75-8
7dz4k6zn32 ,
unii-7dz4k6zn32
alpha-fluoromethylhistidine, (s)-
l-histidine, alpha-(fluoromethyl)-
SCHEMBL60507
DTXSID20224221
.alpha.-fluoromethylhistidine, (s)-
(s)-.alpha.-fluoromethylhistidine
l-histidine, .alpha.-(fluoromethyl)-
.alpha.-(fluoromethyl)-l-histidine
.alpha.-fmh, (s)-
(s)-2-((1h-imidazol-4-yl)methyl)-2-amino-3-fluoropropanoic acid
CHEMBL4117252
PD128846

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
", consistently produced a nearly maximal hypothermic response in non tolerant rats, whereas this dosage induced an elevation of body temperature in tolerant rats."( Modification of rat thermal responses to morphine by alpha-FMH suggests a role for neural histamine in morphine tolerance.
Arrigo-Reina, R; Spadaro, C, 1990
)
0.28
" At a dosage of 100 mg/kg (+/-)-alpha-FMH did not alter histamine-N-methyltransferase, DOPA decarboxylase, and glutamate decarboxylase activities."( Inhibition of histamine synthesis in brain by alpha-fluoromethylhistidine, a new irreversible inhibitor: in vitro and in vivo studies.
Barbin, G; Garbarg, M; Rodergas, E; Schwartz, JC, 1980
)
0.26
" Pretreatment of the rats with an ip bolus injection of alpha-fluoromethylhistidine, a suicide inhibitor of a histidine decarboxylase (HDC), at a dosage of 224 micromol/kg blocked the conversion of histidine into histamine and attenuated the suppressive effect of histidine on food intake from 64."( Histidine suppresses food intake through its conversion into neuronal histamine.
Akehi, Y; Chiba, S; Sakata, T; Tajima, D; Yoshimatsu, H, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (244)

TimeframeStudies, This Drug (%)All Drugs %
pre-199075 (30.74)18.7374
1990's121 (49.59)18.2507
2000's40 (16.39)29.6817
2010's7 (2.87)24.3611
2020's1 (0.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.40%)5.53%
Reviews6 (2.40%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other243 (97.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]